Special Issue "Immunobiology Pathogenesis and Therapeutic Perspectives in Viral Hepatitis"
Deadline for manuscript submissions: 20 December 2019
Hepatitis viruses are a major public health concern, even though their burden is not equally distributed around the world. It was stated in 2012 that they were the 10th leading cause of death and the 16th cause of disability. Even though these viruses are basically different, resulting in different natural disease courses, they share several characteristics or determinants. Their natural disease courses and clinical outcomes are mainly determined by different virological and immunological factors. They are associated with a significant risk of acute liver failure, with fulminant courses with HAV, HBV/HDV, and HEV. HBV and HCV are non-cytopathic viruses that develop mechanisms of escape from immunological control with quantitative and functional defects of virus-specific T-cell response. This allows them to persist and cause hepatic inflammation leading to the development of liver cirrhosis and hepatocellular carcinoma (HCC). In addition, HBV is also oncogenic per se via insertional mutagenesis of cancer related genes, even though all the underlying mechanisms are not fully understood. It is also unclear whether HBV can be completely cleared from human liver. Immune responses are also critical to determine the outcome of HEV infection, which may persist in immunodepressed patients and be more severe among pregnant women. HCV, but above all HBV, can also be transmitted from mother to child, contributing to the spread of epidemics.
Thus, even though dramatic success has been reached in HCV eradication with direct antiviral agents, improving our understanding of the immunopathogenesis of these viruses remains crucial for the development of new therapeutic and preventive strategies for all these viruses, including vaccines. These are the reasons why this supplement is dedicated to immunobiology, pathogenesis, and perspectives in viral hepatitis.
Prof. Lionel Piroth
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Hepatitis virus
- Acute hepatitis
- Chronic hepatitis
- Immune response
- Hepatocellular carcinoma